Dermata says Australian Patent Office accepts Spongilla tech application

Dermata Therapeutics (DRMA) announced the Australian Patent Office has accepted Dermata’s patent application for its Spongilla technology combination as a method for treating acne. The accepted patent application, entitled “Compositions and methods for the treatment of skin conditions,” continues to strengthen Dermata’s global intellectual property portfolio for its Spongilla technology combination for the treatment of acne as it follows the Company’s issued patent in the U.S. The patent will be automatically issued in mid-January 2026, unless a third party files an opposition within the three months after acceptance has been published.